Mitochondrial biology and the identification of biomarkers of Huntington's disease

被引:6
|
作者
Neueder, Andreas [1 ]
Orth, Michael [1 ,2 ]
机构
[1] Ulm Univ, Dept Neurol, Ulm, Germany
[2] Neurozentrum Siloah, SwissHuntingtons Dis Ctr, Worbstr 312, CH-3073 Gumligenbei Bern, Switzerland
关键词
fission and fusion; huntingtin fragment; mitochondrial quality control; mtDNA; splicing; TRANSCRIPTION FACTOR-A; ISOLATED BRAIN MITOCHONDRIA; CYTOCHROME-C RELEASE; YAC128 MOUSE MODEL; COMPLEX-II DEFECTS; DNA COPY NUMBER; MUTANT HUNTINGTIN; STRIATAL NEURONS; CAG REPEAT; NUCLEAR-LOCALIZATION;
D O I
10.2217/nmt-2019-0033
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Apart from finding novel compounds for treating Huntington's disease (HD) an important challenge at present consists in finding reliable read-outs or biomarkers that reflect key biological processes involved in HD pathogenesis. The core elements of HD biology, for example, HTT RNA levels or protein species can serve as biomarker, as could measures from biological systems or pathways in which Huntingtin plays an important role. Here we review the evidence for the involvement of mitochondrial biology in HD. The most consistent findings pertain to mitochondrial quality control, for example, fission/fusion. However, a convincing mitochondrial signature with biomarker potential is yet to emerge. This requires more research including in peripheral sources of human material, such as blood, or skeletal muscle.
引用
收藏
页码:243 / 255
页数:13
相关论文
共 50 条
  • [21] Mitochondrial biology in Alzheimer's disease pathogenesis
    Galindo, Maria F.
    Ikuta, Ichiro
    Zhu, Xiongwei
    Casadesus, Gemma
    Jordan, Joaquin
    JOURNAL OF NEUROCHEMISTRY, 2010, 114 (04) : 933 - 945
  • [22] Mitochondrial and redox modifications in early stages of Huntington's disease
    Lopes, Carla
    Ferreira, I. Luisa
    Maranga, Carina
    Beatriz, Margarida
    Mota, Sandra I.
    Sereno, Jose
    Castelhano, Joao
    Abrunhosa, Antero
    Oliveira, Francisco
    De Rosa, Maura
    Hayden, Michael
    Laco, Mario N.
    Januario, Cristina
    Branco, Miguel Castelo
    Rego, A. Cristina
    REDOX BIOLOGY, 2022, 56
  • [23] Huntington's disease and mitochondrial alterations: emphasis on experimental models
    Perez-De la Cruz, Veronica
    Carrillo-Mora, Paul
    Santamaria, Abel
    JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 2010, 42 (03) : 207 - 215
  • [24] Mitochondrial Dysfunction in Huntington's Disease: Pathogenesis and Therapeutic Opportunities
    Sharma, Aditi
    Behl, Tapan
    Sharma, Lalit
    Aelya, Lotfi
    Bungau, Simona
    CURRENT DRUG TARGETS, 2021, 22 (14) : 1637 - 1667
  • [25] PGC-1α, mitochondrial dysfunction, and Huntington's disease
    Johri, Ashu
    Chandra, Abhishek
    Beal, M. Flint
    FREE RADICAL BIOLOGY AND MEDICINE, 2013, 62 : 37 - 46
  • [26] Mitochondrial functional alterations in relation to pathophysiology of Huntington's disease
    Pandey, Mritunjay
    Mohanakumar, Kochupurackal P.
    Usha, Rajamma
    JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 2010, 42 (03) : 217 - 226
  • [27] Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease
    Kim, Jinho
    Moody, Jennifer P.
    Edgerly, Christina K.
    Bordiuk, Olivia L.
    Cormier, Kerry
    Smith, Karen
    Beal, M. Flint
    Ferrante, Robert J.
    HUMAN MOLECULAR GENETICS, 2010, 19 (20) : 3919 - 3935
  • [28] Mitochondrial HSF1 triggers mitochondrial dysfunction and neurodegeneration in Huntington's disease
    Liu, Chunyue
    Fu, Zixing
    Wu, Shanshan
    Wang, Xiaosong
    Zhang, Shengrong
    Chu, Chu
    Hong, Yuan
    Wu, Wenbo
    Chen, Shengqi
    Jiang, Yueqing
    Wu, Yang
    Song, Yongbo
    Liu, Yan
    Guo, Xing
    EMBO MOLECULAR MEDICINE, 2022, 14 (07)
  • [29] Mitophagy in Huntington's disease
    Sonsky, I
    Vodicka, P.
    Kepkova, K. Vodickova
    Hansikova, H.
    NEUROCHEMISTRY INTERNATIONAL, 2021, 149
  • [30] Antioxidants in Huntington's disease
    Johri, Ashu
    Beal, M. Flint
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2012, 1822 (05): : 664 - 674